Sangamo Therapeutics Secures Over $130 Million in Funding and FDA Fast Track Designation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 15 hours ago
0mins
Should l Buy SGMO?
Source: Yahoo Finance
- Funding Progress: Since the beginning of 2025, Sangamo Therapeutics has raised over $130 million through non-dilutive license fees, milestone payments, and equity financing, providing essential funding for ongoing research and enhancing its competitive position in the market.
- Clinical Advancement: The company has initiated a rolling submission of a Biologics License Agreement (BLA) for ST-920 to the FDA, having completed both non-clinical and clinical modules, marking its first wholly-owned BLA submission that could expedite the FDA approval process.
- Fast Track Designation: Sangamo received Fast Track designation from the FDA for SC503, an investigational treatment for intractable pain due to small fiber neuropathy, highlighting its potential to address significant unmet medical needs in this area.
- Clinical Trial Activation: Six clinical sites have been activated for the Phase I/II STAN study in chronic neuropathic pain, demonstrating the company's proactive efforts in advancing clinical research to provide new treatment options for patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SGMO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SGMO
Wall Street analysts forecast SGMO stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 0.307
Low
1.00
Averages
3.75
High
10.00
Current: 0.307
Low
1.00
Averages
3.75
High
10.00
About SGMO
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sangamo Therapeutics Secures Over $130 Million in Funding and FDA Fast Track Designation
- Funding Progress: Since the beginning of 2025, Sangamo Therapeutics has raised over $130 million through non-dilutive license fees, milestone payments, and equity financing, providing essential funding for ongoing research and enhancing its competitive position in the market.
- Clinical Advancement: The company has initiated a rolling submission of a Biologics License Agreement (BLA) for ST-920 to the FDA, having completed both non-clinical and clinical modules, marking its first wholly-owned BLA submission that could expedite the FDA approval process.
- Fast Track Designation: Sangamo received Fast Track designation from the FDA for SC503, an investigational treatment for intractable pain due to small fiber neuropathy, highlighting its potential to address significant unmet medical needs in this area.
- Clinical Trial Activation: Six clinical sites have been activated for the Phase I/II STAN study in chronic neuropathic pain, demonstrating the company's proactive efforts in advancing clinical research to provide new treatment options for patients.
See More
PEPG, SGMO, and PHR Shares Decline Amid Disappointing Results
- PEPG Trial Disappointment: PepGen's Phase 2 Freedom 2 study results showed no significant improvements in walking speed or hand strength at the starting dose of 5 mg/kg, leading to a 45% plunge in premarket trading, reflecting investor disappointment in the therapy's efficacy.
- SGMO Earnings Miss: Sangamo Therapeutics reported a Q4 loss per share of $0.11, wider than the expected $0.05 loss, despite revenue rising to $14.23 million, indicating pressure on the company's funding outlook that may impact future operations.
- PHR Revenue Outlook Cut: Phreesia lowered its fiscal 2027 revenue outlook to $510 million to $520 million, below analyst expectations of $552.1 million, resulting in a 27% drop in share price and prompting downgrades from multiple brokerages.
- Market Sentiment Fluctuates: While retail sentiment for PEPG, SGMO, and PHR on Stocktwits was 'extremely bullish', the disappointing performance and unclear outlook have severely undermined investor confidence, reflecting a cautious attitude towards biotech stocks.
See More
Sangamo Therapeutics Q4 2025 Earnings Call Insights
- Significant Pipeline Progress: Sangamo made notable advancements in 2025, particularly with positive results from the registrational STAAR study for Fabry disease, where the eGFR slope at 52 weeks was promising, and the FDA confirmed this may serve as the primary basis for accelerated approval, indicating the company's ability to achieve positive outcomes amid regulatory complexities.
- BLA Submission Progress: The company is advancing its first wholly owned BLA's rolling submission, with expectations to complete it as early as this summer, despite facing challenges related to limited cash resources, which will lay the groundwork for future commercialization efforts.
- Successful Fundraising: Since the beginning of 2025, Sangamo has raised over $130 million through nondilutive license fees, milestone payments, and equity financing, providing essential financial support for ongoing R&D and market expansion initiatives.
- Neurology Pipeline Expansion: The company has activated six clinical sites in the STAND study and entered into a third neurology capsid license agreement with Eli Lilly to deliver genomic medicines for up to five CNS disease targets, demonstrating its strategic positioning in the neurology sector.
See More
Sangamo Therapeutics Reports Q4 Loss and Revenue Miss
- Disappointing Earnings: Sangamo Therapeutics reported a Q4 GAAP EPS of -$0.11, missing expectations by $0.12, indicating ongoing challenges in profitability that may affect investor confidence.
- Weak Revenue Growth: Despite an 88.5% year-over-year revenue increase to $14.23 million, the figure fell short of the $26.02 million forecast, reflecting unmet market demand that could negatively impact future fundraising capabilities.
- 2026 Financial Guidance: The company anticipates GAAP operating expenses to range from $120 million to $140 million in 2026, including approximately $8 million in non-cash stock-based compensation and $2 million in depreciation and amortization, highlighting pressure on cost management.
- Non-GAAP Expense Outlook: Expected non-GAAP operating expenses for 2026 are projected between $110 million and $120 million, excluding non-cash stock compensation and depreciation, indicating efforts to optimize financial structure in response to future challenges.
See More
Multiple Companies Set to Report Earnings
- Progress Software Earnings Outlook: Progress Software Corporation (PRGS) is expected to report earnings per share of $1.18, reflecting a 10.28% increase year-over-year, indicating the company's consistent ability to exceed market expectations, which may further boost investor confidence.
- Phreesia Earnings Surge: Phreesia, Inc. (PHR) forecasts earnings per share of $0.09, representing a staggering 181.82% increase compared to the same quarter last year, highlighting the company's strong performance in the medical information systems sector, potentially attracting more investor interest.
- Virgin Galactic Earnings Forecast: Virgin Galactic Holdings, Inc. (SPCE) anticipates earnings per share of -$1.12, although still negative, this marks a 55.73% improvement year-over-year, suggesting recovery potential in the aerospace sector, which may influence market perceptions of its future growth.
- HireQuest Earnings Decline: HireQuest, Inc. (HQI) expects earnings per share of $0.12, down 36.84% from the same quarter last year, reflecting challenges faced in the staffing industry, which could negatively impact its stock price.
See More
Major Earnings Reports Expected After Monday's Close
- Earnings Release Companies: Major companies expected to report earnings after Monday's close include Virgin Galactic Holdings (SPCE), Anadarko Petroleum Corp. (APC), Sangamo Therapeutics (SGMO), Standard Lithium Ltd. (SLI), and Spruce Power Holding Corporation (SPRU), all of which hold significant positions in their respective markets.
- Market Focus: Investors will closely monitor these earnings reports to assess financial performance and future growth potential, particularly in the current economic climate where profitability expectations are crucial.
- Additional Earnings Announcements: In addition to the aforementioned companies, other earnings reports are slated for release after Monday's close, including [[DFDV]], [[INMB]], [[PHR]], and [[PRGS]], which may impact their respective industries.
- Earnings Season Calendar: Seeking Alpha provides a comprehensive earnings season calendar, allowing investors to access more information to better navigate market dynamics and investment opportunities.
See More
Sangamo Therapeutics Secures Over $130 Million in Funding and FDA Fast Track Designation
- Funding Progress: Since the beginning of 2025, Sangamo Therapeutics has raised over $130 million through non-dilutive license fees, milestone payments, and equity financing, providing essential funding for ongoing research and enhancing its competitive position in the market.
- Clinical Advancement: The company has initiated a rolling submission of a Biologics License Agreement (BLA) for ST-920 to the FDA, having completed both non-clinical and clinical modules, marking its first wholly-owned BLA submission that could expedite the FDA approval process.
- Fast Track Designation: Sangamo received Fast Track designation from the FDA for SC503, an investigational treatment for intractable pain due to small fiber neuropathy, highlighting its potential to address significant unmet medical needs in this area.
- Clinical Trial Activation: Six clinical sites have been activated for the Phase I/II STAN study in chronic neuropathic pain, demonstrating the company's proactive efforts in advancing clinical research to provide new treatment options for patients.
See More
PEPG, SGMO, and PHR Shares Decline Amid Disappointing Results
- PEPG Trial Disappointment: PepGen's Phase 2 Freedom 2 study results showed no significant improvements in walking speed or hand strength at the starting dose of 5 mg/kg, leading to a 45% plunge in premarket trading, reflecting investor disappointment in the therapy's efficacy.
- SGMO Earnings Miss: Sangamo Therapeutics reported a Q4 loss per share of $0.11, wider than the expected $0.05 loss, despite revenue rising to $14.23 million, indicating pressure on the company's funding outlook that may impact future operations.
- PHR Revenue Outlook Cut: Phreesia lowered its fiscal 2027 revenue outlook to $510 million to $520 million, below analyst expectations of $552.1 million, resulting in a 27% drop in share price and prompting downgrades from multiple brokerages.
- Market Sentiment Fluctuates: While retail sentiment for PEPG, SGMO, and PHR on Stocktwits was 'extremely bullish', the disappointing performance and unclear outlook have severely undermined investor confidence, reflecting a cautious attitude towards biotech stocks.
See More
Sangamo Therapeutics Q4 2025 Earnings Call Insights
- Significant Pipeline Progress: Sangamo made notable advancements in 2025, particularly with positive results from the registrational STAAR study for Fabry disease, where the eGFR slope at 52 weeks was promising, and the FDA confirmed this may serve as the primary basis for accelerated approval, indicating the company's ability to achieve positive outcomes amid regulatory complexities.
- BLA Submission Progress: The company is advancing its first wholly owned BLA's rolling submission, with expectations to complete it as early as this summer, despite facing challenges related to limited cash resources, which will lay the groundwork for future commercialization efforts.
- Successful Fundraising: Since the beginning of 2025, Sangamo has raised over $130 million through nondilutive license fees, milestone payments, and equity financing, providing essential financial support for ongoing R&D and market expansion initiatives.
- Neurology Pipeline Expansion: The company has activated six clinical sites in the STAND study and entered into a third neurology capsid license agreement with Eli Lilly to deliver genomic medicines for up to five CNS disease targets, demonstrating its strategic positioning in the neurology sector.
See More
Sangamo Therapeutics Reports Q4 Loss and Revenue Miss
- Disappointing Earnings: Sangamo Therapeutics reported a Q4 GAAP EPS of -$0.11, missing expectations by $0.12, indicating ongoing challenges in profitability that may affect investor confidence.
- Weak Revenue Growth: Despite an 88.5% year-over-year revenue increase to $14.23 million, the figure fell short of the $26.02 million forecast, reflecting unmet market demand that could negatively impact future fundraising capabilities.
- 2026 Financial Guidance: The company anticipates GAAP operating expenses to range from $120 million to $140 million in 2026, including approximately $8 million in non-cash stock-based compensation and $2 million in depreciation and amortization, highlighting pressure on cost management.
- Non-GAAP Expense Outlook: Expected non-GAAP operating expenses for 2026 are projected between $110 million and $120 million, excluding non-cash stock compensation and depreciation, indicating efforts to optimize financial structure in response to future challenges.
See More
Multiple Companies Set to Report Earnings
- Progress Software Earnings Outlook: Progress Software Corporation (PRGS) is expected to report earnings per share of $1.18, reflecting a 10.28% increase year-over-year, indicating the company's consistent ability to exceed market expectations, which may further boost investor confidence.
- Phreesia Earnings Surge: Phreesia, Inc. (PHR) forecasts earnings per share of $0.09, representing a staggering 181.82% increase compared to the same quarter last year, highlighting the company's strong performance in the medical information systems sector, potentially attracting more investor interest.
- Virgin Galactic Earnings Forecast: Virgin Galactic Holdings, Inc. (SPCE) anticipates earnings per share of -$1.12, although still negative, this marks a 55.73% improvement year-over-year, suggesting recovery potential in the aerospace sector, which may influence market perceptions of its future growth.
- HireQuest Earnings Decline: HireQuest, Inc. (HQI) expects earnings per share of $0.12, down 36.84% from the same quarter last year, reflecting challenges faced in the staffing industry, which could negatively impact its stock price.
See More
Major Earnings Reports Expected After Monday's Close
- Earnings Release Companies: Major companies expected to report earnings after Monday's close include Virgin Galactic Holdings (SPCE), Anadarko Petroleum Corp. (APC), Sangamo Therapeutics (SGMO), Standard Lithium Ltd. (SLI), and Spruce Power Holding Corporation (SPRU), all of which hold significant positions in their respective markets.
- Market Focus: Investors will closely monitor these earnings reports to assess financial performance and future growth potential, particularly in the current economic climate where profitability expectations are crucial.
- Additional Earnings Announcements: In addition to the aforementioned companies, other earnings reports are slated for release after Monday's close, including [[DFDV]], [[INMB]], [[PHR]], and [[PRGS]], which may impact their respective industries.
- Earnings Season Calendar: Seeking Alpha provides a comprehensive earnings season calendar, allowing investors to access more information to better navigate market dynamics and investment opportunities.
See More
